MUDr. Dana Maňasková

  • medicinman.cz
  • Zájmy a činnosti
  • Nemoci a symptomy
  • Léky, látky a laboratorní testy
  • Postupy, metody a terapie
  • Dietologie a potravinářství
  • P-o-traviny, rostliny aj.
  • Papírování
  • Zajímaví lidé a činnosti
  • Odborná pracoviště
  • Odborné odkazy
  • Obecné odkazy a tipy
  • Kalendář akcí
  • CV a kredity
  • Fantazie, nápady a snění
  • GDPR

Vyhledávání na medicinman.cz
 

nemoci-sympt/GYNEKOLOGIE/tehotenstvi-hiv

Profylaxe žen s HIV během těhotenství

  • Most studies demonstrated that TMP-SMZ was not associated with hyperbilirubinemia when administered to mothers during pregnancy and breastfeeding.
  • No cases of kernicterus were reported in neonates after maternal ingestion of sulfonamides.
  • There is mixed evidence linking ingestion of TMP-SMZ and other sulfonamides in early pregnancy to elevated risks of:
    • Oral clefts
    • Neural tube defects
    • Cardiovascular
    • Urinary tract abnormalities
  • Some sources found that supplementation with folic acid might ameliorate this potential risk
  • Existing guidelines recommend that HIV-infected pregnant women receive prophylaxis, but they differ with regards to:
    • Stage of disease
    • CD4+ T-lymphocyte count
    • Prophylaxis during the 1st trimester.
  • Existing data indicate that the risk of serious injury to neonates from maternal use of daily TMP-SMZ prophylaxis during pregnancy and breastfeeding is small.
  • Given the substantial benefits of TMP-SMZ prophylaxis for HIV-infected women living in resource-limited settings
  • This review indicates that:
    • It is safe to abide by the WHO guidelines recommending daily TMP-SMZ prophylaxis for HIV-infected pregnant women.
O úroveň výše

Poslední aktualizace: 1. 8. 2022 0:26:30
© Dana Maňasková, metabalance.cz
e-mail